Mansbridge Margaret, Chung Eric, Rhee Handoo
Department of Urology, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, QLD 4102 Australia.
University of Queensland, St Lucia, QLD 4067, Australia.
Med Sci (Basel). 2019 Aug 5;7(8):85. doi: 10.3390/medsci7080085.
Multi-parametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) using prostate-specific membrane antigen (PSMA) targeting ligands have been adopted as a new standard of imaging modality in the management of prostate cancer (PCa). Technological advances with hybrid and advanced computer-assisted technologies such as MR/PET, MR/US, multi-parametric US, and robotic biopsy systems, have resulted in improved diagnosis and staging of patients in various stages of PCa with changes in treatment that may be considered "personalized". Whilst newer clinical trials incorporate these novel imaging modalities into study protocols and as long-term data matures, patients should be made aware of the potential benefits and harm related to these technologies. Published literature needs to report longer-term treatment efficacy, health economic outcomes, and adverse effects. False positives and negatives of these imaging modalities have the potential to cause harm and the limitations of these technologies should be appreciated. The role of a multi-disciplinary team (MDT) and a shared-decision-making model are important to ensure that all aspects of the novel imaging modalities are considered.
多参数磁共振成像（mpMRI）以及使用靶向前列腺特异性膜抗原（PSMA）配体的正电子发射断层扫描（PET）已被用作前列腺癌（PCa）管理中成像方式的新标准。诸如MR/PET、MR/US、多参数超声和机器人活检系统等混合及先进计算机辅助技术的技术进步，已改善了处于PCa不同阶段患者的诊断和分期，治疗方式也有所改变，这些改变可被视为“个性化”的。虽然更新的临床试验将这些新型成像方式纳入研究方案，且随着长期数据的成熟，但应让患者了解与这些技术相关的潜在益处和危害。已发表的文献需要报告长期治疗疗效、健康经济结果和不良反应。这些成像方式的假阳性和假阴性有可能造成危害，应认识到这些技术的局限性。多学科团队（MDT）的作用和共同决策模型对于确保考虑新型成像方式的所有方面很重要。
